Clinical reality: The safety and efficacy of the world's first CFC-free MDI

E. Bleecker

Clinical reality: The safety and efficacy of the world's first CFC-free MDI

E. Bleecker

Research output: Contribution to journal › Article › peer-review

Abstract

This paper describes clinical studies comparing a new chlorofluorocarbon (CFC)-free salbutamol sulphate metered-dose inhaler with current CFC-formulations. Such studies are vital to ensure a smooth transition for asthmatic patients who switch to the new inhalers as CFC-containing products are phased out. The results of the studies described confirm hydrofluoroalkane (HFA)-134a salbutamol as a suitable alternative to the CFC comparator formulations tested.

Original language	English (US)
Pages (from-to)	37-39
Number of pages	3
Journal	European Respiratory Review
Volume	7
Issue number	41
State	Published - 1997
Externally published	Yes

Keywords

Asthma
CFC-free
Metered-dose inhalers
Salbutamol

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Cite this

@article{2bf05cb4c42543e8979015daac459ef0,

title = "Clinical reality: The safety and efficacy of the world's first CFC-free MDI",

abstract = "This paper describes clinical studies comparing a new chlorofluorocarbon (CFC)-free salbutamol sulphate metered-dose inhaler with current CFC-formulations. Such studies are vital to ensure a smooth transition for asthmatic patients who switch to the new inhalers as CFC-containing products are phased out. The results of the studies described confirm hydrofluoroalkane (HFA)-134a salbutamol as a suitable alternative to the CFC comparator formulations tested.",

keywords = "Asthma, CFC-free, Metered-dose inhalers, Salbutamol",

author = "E. Bleecker",

year = "1997",

language = "English (US)",

volume = "7",

pages = "37--39",

journal = "European Respiratory Review",

issn = "0905-9180",

publisher = "European Respiratory Society",

number = "41",

}

TY - JOUR

T1 - Clinical reality

T2 - The safety and efficacy of the world's first CFC-free MDI

AU - Bleecker, E.

PY - 1997

Y1 - 1997

N2 - This paper describes clinical studies comparing a new chlorofluorocarbon (CFC)-free salbutamol sulphate metered-dose inhaler with current CFC-formulations. Such studies are vital to ensure a smooth transition for asthmatic patients who switch to the new inhalers as CFC-containing products are phased out. The results of the studies described confirm hydrofluoroalkane (HFA)-134a salbutamol as a suitable alternative to the CFC comparator formulations tested.

AB - This paper describes clinical studies comparing a new chlorofluorocarbon (CFC)-free salbutamol sulphate metered-dose inhaler with current CFC-formulations. Such studies are vital to ensure a smooth transition for asthmatic patients who switch to the new inhalers as CFC-containing products are phased out. The results of the studies described confirm hydrofluoroalkane (HFA)-134a salbutamol as a suitable alternative to the CFC comparator formulations tested.

KW - Asthma

KW - CFC-free

KW - Metered-dose inhalers

KW - Salbutamol

UR - https://www.scopus.com/pages/publications/0030983328

UR - https://www.scopus.com/pages/publications/0030983328#tab=citedBy

M3 - Article

AN - SCOPUS:0030983328

SN - 0905-9180

VL - 7

SP - 37

EP - 39

JO - European Respiratory Review

JF - European Respiratory Review

IS - 41

ER -

Clinical reality: The safety and efficacy of the world's first CFC-free MDI

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this